MedTrace Logo

JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese Population

NCT04891419 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2024-12-12

Study results available
· View outcomes & findings →

Summary

The objectives of this study are to evaluate the safety and effectiveness of JUVÉDERM® VOLUMA® with Lidocaine injectable gel in adult Chinese population seeking correction of temple hollowing.

Conditions

  • Temple Hollowing

Interventions

DEVICE

JUVÉDERM® VOLUMA® with Lidocaine

JUVÉDERM® VOLUMA® with Lidocaine injectable gel

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • ALLERGAN, INC. · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-20
Primary Completion
2023-11-22
Completion
2023-11-22
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04891419 on ClinicalTrials.gov